TY - JOUR
T1 - Trends in Black-White Differences of Antihypertensive Treatment in Individuals With and Without History of Stroke
AU - Stamm, Brian
AU - Royan, Regina
AU - Cui, Jinhong
AU - Long, D. Leann
AU - Lineback, Christina M.
AU - Akinyelure, Oluwasegun P.
AU - Plante, Timothy B.
AU - Levine, Deborah A.
AU - Howard, Virginia J.
AU - Howard, George
AU - Gorelick, Philip B.
N1 - Publisher Copyright:
© 2024 American Heart Association, Inc.
PY - 2024/8/1
Y1 - 2024/8/1
N2 - BACKGROUND: Recent hypertension guidelines for the general population have included race-specific recommendations for antihypertensives, whereas current stroke-specific recommendations for antihypertensives do not vary by race. The impact of these guidelines on antihypertensive regimen changes over time, and if this has varied by prevalent stroke status, is unclear. METHODS: The use of antihypertensive medications was studied cross-sectionally among self-identified Black and White participants, aged ≥45 years, with and without history of stroke, from the REGARDS study (Reasons for Geographic and Racial Differences in Stroke). Participants completed an in-home examination in 2003–2007 (visit 1) with/without an examination in 2013–2016 (visit 2). Stratified by prevalent stroke status, logistic regression mixed models examined associations between antihypertensive class use for visit 2 versus visit 1 and Black versus White individuals with an interaction adjusted for demographics, socioeconomic status, and vascular risk factors/vital signs. RESULTS: Of 17 244 stroke-free participants at visit 1, Black participants had greater adjusted odds of angiotensin-converting enzyme inhibitor usage than White participants (odds ratio [OR], 1.51 [95% CI, 1.30–1.77]). This difference was smaller in the 7476 stroke-free participants at visit 2 (OR, 1.16 [95% CI, 1.08–1.25]). In stroke-free participants at visit 1, Black participants had lower odds of calcium channel blocker (CCB) usage than White participants (OR, 0.47 [95% CI, 0.41–0.55]), but CCB usage did not differ significantly between Black and White stroke-free participants at visit 2 (OR, 1.02 [95% CI, 0.95–1.09]). Among 1437 stroke survivor participants at visit 1, Black participants had lower odds of CCB use than White participants (OR, 0.34 [95% CI, 0.26–0.45]). In 689 stroke survivor participants at visit 2, CCB use did not differ between Black and White participants (OR, 0.80 [95% CI, 0.61–1.06]). CONCLUSIONS: Racial differences in the use of guideline-recommended antihypertensives decreased between 2003–2007 and 2013–2016 in stroke-free individuals. In stroke survivors, racial differences in CCB usage narrowed over the time periods. These findings suggest there is still a mismatch between race-specific hypertension guidelines and recent clinical practice.
AB - BACKGROUND: Recent hypertension guidelines for the general population have included race-specific recommendations for antihypertensives, whereas current stroke-specific recommendations for antihypertensives do not vary by race. The impact of these guidelines on antihypertensive regimen changes over time, and if this has varied by prevalent stroke status, is unclear. METHODS: The use of antihypertensive medications was studied cross-sectionally among self-identified Black and White participants, aged ≥45 years, with and without history of stroke, from the REGARDS study (Reasons for Geographic and Racial Differences in Stroke). Participants completed an in-home examination in 2003–2007 (visit 1) with/without an examination in 2013–2016 (visit 2). Stratified by prevalent stroke status, logistic regression mixed models examined associations between antihypertensive class use for visit 2 versus visit 1 and Black versus White individuals with an interaction adjusted for demographics, socioeconomic status, and vascular risk factors/vital signs. RESULTS: Of 17 244 stroke-free participants at visit 1, Black participants had greater adjusted odds of angiotensin-converting enzyme inhibitor usage than White participants (odds ratio [OR], 1.51 [95% CI, 1.30–1.77]). This difference was smaller in the 7476 stroke-free participants at visit 2 (OR, 1.16 [95% CI, 1.08–1.25]). In stroke-free participants at visit 1, Black participants had lower odds of calcium channel blocker (CCB) usage than White participants (OR, 0.47 [95% CI, 0.41–0.55]), but CCB usage did not differ significantly between Black and White stroke-free participants at visit 2 (OR, 1.02 [95% CI, 0.95–1.09]). Among 1437 stroke survivor participants at visit 1, Black participants had lower odds of CCB use than White participants (OR, 0.34 [95% CI, 0.26–0.45]). In 689 stroke survivor participants at visit 2, CCB use did not differ between Black and White participants (OR, 0.80 [95% CI, 0.61–1.06]). CONCLUSIONS: Racial differences in the use of guideline-recommended antihypertensives decreased between 2003–2007 and 2013–2016 in stroke-free individuals. In stroke survivors, racial differences in CCB usage narrowed over the time periods. These findings suggest there is still a mismatch between race-specific hypertension guidelines and recent clinical practice.
KW - antihypertensive agents
KW - calcium channel blockers
KW - hypertension
KW - racial groups
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85199280026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85199280026&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.124.046877
DO - 10.1161/STROKEAHA.124.046877
M3 - Article
C2 - 39038094
AN - SCOPUS:85199280026
SN - 0039-2499
VL - 55
SP - 2034
EP - 2044
JO - Stroke
JF - Stroke
IS - 8
ER -